Here, we show that the change of IL-10 mRNA expression and IL-6/IL-10 ratio during the first two weeks after CS therapy initiation can be used as biomarkers for refractoriness to CS treatment in uveitis patients independent of etiology of disease. This evidence concerns the gene IL10 and uveitis.